Novartis Announces Pluvicto's New Data From PSMAddition Shows Enhanced Prostate-Specific Antigen Responses; Risk Of Prostate-Specific Antigen Lowered By 58%

Benzinga Newsdesk www.benzinga.com Positive 95.5%

Neg 0% Neu 0% Pos 95.5%

Comments

No comments yet. Be the first!